NYSEARCA:VNRX - American Stock Exchange - US9286611077 - Common Stock
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
VNRX stock results show that VolitionRX beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
VNRX stock results show that VolitionRX beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
VNRX stock results show that VolitionRX met analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
With our improving economy, you need to invest in these top biotech stocks that are looking to strike gold this year.
VolitionRx receives $13M milestone payments from Heska Corporation for successful assay transfer, causing VNRX shares to surge 36.7%.
VolitionRx director, Guy Archibald Innes, acquires $14,200 worth of stock, buying 20,000 shares at $0.71, increasing his total holding to 597,161 shares.
VolitionRx (VNRX) prices an underwritten public offering of shares, whereby underwriters will be granted a 30-day option to purchase up to an additional 15% shares.The final terms and...